PT3092223T - (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbenzil)pirrolidin-2-ona e os seus profármacos para o tratamento de distúrbios psiquiátricos - Google Patents

(r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbenzil)pirrolidin-2-ona e os seus profármacos para o tratamento de distúrbios psiquiátricos

Info

Publication number
PT3092223T
PT3092223T PT157023128T PT15702312T PT3092223T PT 3092223 T PT3092223 T PT 3092223T PT 157023128 T PT157023128 T PT 157023128T PT 15702312 T PT15702312 T PT 15702312T PT 3092223 T PT3092223 T PT 3092223T
Authority
PT
Portugal
Prior art keywords
methylbenzyl
pyrrolidin
piperidin
prodrugs
hydroxyphenyl
Prior art date
Application number
PT157023128T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3092223T publication Critical patent/PT3092223T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PT157023128T 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbenzil)pirrolidin-2-ona e os seus profármacos para o tratamento de distúrbios psiquiátricos PT3092223T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925405P 2014-01-09 2014-01-09

Publications (1)

Publication Number Publication Date
PT3092223T true PT3092223T (pt) 2020-02-19

Family

ID=52444626

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157023128T PT3092223T (pt) 2014-01-09 2015-01-08 (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbenzil)pirrolidin-2-ona e os seus profármacos para o tratamento de distúrbios psiquiátricos

Country Status (27)

Country Link
US (10) US9187506B2 (enExample)
EP (2) EP3677578A1 (enExample)
JP (1) JP6629738B2 (enExample)
KR (1) KR102331120B1 (enExample)
AR (1) AR102019A1 (enExample)
AU (1) AU2015204785A1 (enExample)
CA (1) CA2936338A1 (enExample)
CL (1) CL2016001744A1 (enExample)
CY (1) CY1122768T1 (enExample)
DK (1) DK3092223T3 (enExample)
EA (1) EA201691133A1 (enExample)
ES (1) ES2771825T3 (enExample)
HR (1) HRP20200161T1 (enExample)
HU (1) HUE048750T2 (enExample)
IL (1) IL246596A0 (enExample)
LT (1) LT3092223T (enExample)
MX (1) MX2016008715A (enExample)
PE (1) PE20160898A1 (enExample)
PL (1) PL3092223T3 (enExample)
PT (1) PT3092223T (enExample)
RS (1) RS59858B1 (enExample)
SG (1) SG11201605620QA (enExample)
SI (1) SI3092223T1 (enExample)
SM (1) SMT202000094T1 (enExample)
TW (1) TW201612169A (enExample)
UY (1) UY35946A (enExample)
WO (1) WO2015105929A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2018004256A (es) 2015-10-14 2018-05-16 Squibb Bristol Myers Co Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CA3001894A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks
WO2024197289A1 (en) * 2023-03-22 2024-09-26 Gilgamesh Pharmaceuticals, Inc. Negative allosteric modulators of glun2b receptors and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
MXPA02009659A (es) 2000-04-26 2003-03-10 Warner Lambert Co Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda.
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
KR20060017839A (ko) 2003-06-04 2006-02-27 머크 앤드 캄파니 인코포레이티드 Nmda/nr2b 길항제로서 3-플루오로-피페리딘
MXPA06003748A (es) 2003-10-08 2006-06-14 Pfizer Compuestos de lactama condensada.
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질
CN102036985A (zh) * 2007-11-13 2011-04-27 沃泰克斯药物股份有限公司 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
CN105873915A (zh) 2016-08-17
US20190314392A1 (en) 2019-10-17
HUE048750T2 (hu) 2020-08-28
US20170065573A1 (en) 2017-03-09
TW201612169A (en) 2016-04-01
KR102331120B1 (ko) 2021-11-24
US20200297742A1 (en) 2020-09-24
KR20160101194A (ko) 2016-08-24
CA2936338A1 (en) 2015-07-16
PE20160898A1 (es) 2016-09-10
MX2016008715A (es) 2016-09-06
CL2016001744A1 (es) 2017-03-17
DK3092223T3 (da) 2020-03-16
EP3092223B1 (en) 2019-12-11
EP3677578A1 (en) 2020-07-08
US20180104265A1 (en) 2018-04-19
WO2015105929A1 (en) 2015-07-16
ES2771825T3 (es) 2020-07-07
LT3092223T (lt) 2020-02-25
RS59858B1 (sr) 2020-02-28
US20150191496A1 (en) 2015-07-09
US20160030456A1 (en) 2016-02-04
US20180250316A1 (en) 2018-09-06
SMT202000094T1 (it) 2020-03-13
JP6629738B2 (ja) 2020-01-15
SI3092223T1 (sl) 2020-02-28
US20170216325A1 (en) 2017-08-03
HRP20200161T1 (hr) 2020-05-01
US20190125770A1 (en) 2019-05-02
AR102019A1 (es) 2017-02-01
JP2017503804A (ja) 2017-02-02
SG11201605620QA (en) 2016-08-30
EA201691133A1 (ru) 2017-05-31
CY1122768T1 (el) 2021-05-05
AU2015204785A1 (en) 2016-08-25
PL3092223T3 (pl) 2020-05-18
IL246596A0 (en) 2016-08-31
UY35946A (es) 2015-07-31
EP3092223A1 (en) 2016-11-16
US20170340653A1 (en) 2017-11-30
US9187506B2 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
IL275482A (en) Asketamine for the treatment of depression
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
GB2553919B (en) Biomass treatment apparatus
IL290955A (en) Compounds for the treatment of glycogen storage disorders
IL286000A (en) Asketamine for the treatment of depression
IL283948A (en) Methods for treating depression
IL256350A (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
SG11201808685SA (en) Composition for improving brain function for neonates
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
IL263161B (en) New compounds for the treatment of parasitic diseases
IL246596A0 (en) ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders
PL3539138T3 (pl) Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych
GB201612043D0 (en) Composition for treatment of disorders
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
SI3423440T1 (sl) 5-metil-6-fenil-4,5-dihidro-2H-piridazin-3-ON derivat za zdravljenje možganskih tumorjev
EP3466354A4 (en) GREIF TREATMENT INSTRUMENT
EP3104712A4 (en) Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
PL3245014T3 (pl) Sposób rozkładu materiału biomasy zawierającego lignocelulozę
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
HK1225024A1 (en) (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
GB201715833D0 (en) Wood treatment process
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia